Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005875 · ClinicalTrials.gov registry record · NA
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
A NA study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01005875: Clinical Trial NA study, sponsored by University of Alabama at Birmingham.
NCT01005875 is a NA study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01005875, a NA study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Primary Outcome
Number of subjects experiencing a Grade 5 toxicity related to SBRT and sorafenib
Interventions
- DRUG Sorafenib
- RADIATION Stereotactic Body Radiotherapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-06 |
| Phase | NA |
Why NCT01005875 stopped before completion
NCT01005875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01005875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01005875 about?
NCT01005875 is a clinical study titled "Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma". This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
What is the current status of trial NCT01005875?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01005875?
The interventions under investigation include: Sorafenib (DRUG), Stereotactic Body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01005875?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01005875's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia